press-release article 2021-08-19 research;covid-19-coronavirus;substance-use
Press Release5 Minute ReadAug | 19 | 2021
Study reveals trends in opioid overdose deaths in nine states during the COVID-19 pandemic
Michael Morrison617-724-6425mdmorrison@mgh.harvard.edu
During the COVID-19 pandemic, opioid overdose death rates increased in 5 of 9 states examined: Alaska, Colorado, Indiana, North Carolina, and Rhode Island. These increases reflect emergent trends that were not present in the previous two years.
In some states, the types of opioids involved in overdose deaths have changed since the start of the pandemic.
The demographic groups most affected by opioid overdose may be shifting.
Lagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses.
Mohammad S. Jalali, PhD, MSc
Institute for Technology Assessment, Massachusetts General Hospital
BOSTON – The COVID-19 pandemic has disrupted the social support and economic stability of many individuals, which experts have warned could lead to a rise in opioid overdoses and opioid-related deaths. In a recent study shared on medRxiv, researchers at Massachusetts General Hospital (MGH) and Harvard Medical School characterized how the nature of such deaths have changed in nine9 U.S. states since the onset of the pandemic.
The study examined trends in opioid overdose deaths in Alaska, Colorado, Connecticut, Indiana, Massachusetts, North Carolina, Rhode Island, Utah and Wyoming during the COVID-19 pandemic as compared with 2018 and 2019.
The analysis revealed various trends that arose during the pandemic:
Opioid overdose death rates increased in five of the nine states: Alaska, Colorado, Indiana, North Carolina, and Rhode Island.
The types of opioids involved in overdose deaths are changing. For example, Alaska, Colorado, Connecticut, Indiana, and North Carolina experienced a simultaneous increase in the presence of synthetic opioids and a decrease in the presence of heroin among opioid overdose deaths. Also, there was a significant increase in the proportion of opioid overdose deaths involving cocaine in Alaska and Colorado and psychostimulants in Massachusetts.
The demographic groups most affected by opioid overdose may be shifting. For example, there were increases in the proportion of males who died from opioid overdoses in Colorado and Indiana.
"Drug overdose data are collected and reported more slowly than COVID-19 data, from about 4 to 8 months' lag in Massachusetts and North Carolina to over one year in Maryland and Ohio," says senior author Mohammad S. Jalali, PhD, MSc, a senior scientist at MGH's Institute for Technology Assessment and an assistant professor at Harvard Medical School. "This lagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses."
The results may be useful for identifying and treating at-risk individuals. "Practitioners and policy makers can use our findings to help them anticipate which groups of people might be most affected by opioid overdose and which types of policy interventions might be most effective given each state's unique situation," says lead author Gian-Gabriel P. Garcia, PhD, who was a postdoctoral fellow at MGH and Harvard Medical School during the study and is currently an assistant professor at Georgia Tech.
Co-authors of the study include Erin J. Stringfellow, PhD, MSW, Catherine DiGennaro, BA1,
Nicole Poellinger, MPH, Jaden Wood, BA, and Sarah Wakeman, MD.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America's Best Hospitals."
Jan | 14 | 2022
Mathematical model may help improve treatments and clinical trials of patients with COVID-19 and other illnesses
Model reveals certain biological markers that differ based on patient characteristics and response to treatment.
First study to detect Delta variant of SARS-CoV-2 in maternal bloodstream and placenta in cases of stillbirth and pregnancy complications
Findings help elucidate earlier research suggesting that the Delta variant is a threat in pregnancy.
Skin-related side effects indicate better prognosis for patients taking certain cancer drugs
Patients with side effects from immune checkpoint inhibitors tend to live longer.
Brain-based method to determine impairment from cannabis intoxication is reported by researchers
A new study shows that imaging of brain activity with functional near-infrared spectroscopy might offer a more accurate and reliable way to distinguish impairment from cannabis intoxication
Statement from Mass General on COVID-19 information attributed to Edward Ryan, MD
Statement from Mass General on COVID-19 information attributed to Edward Ryan, MD.
Jan | 6 | 2022
Booster dose of mRNA COVID-19 vaccine is required for immune protection against Omicron variant of SARS-CoV-2
Tests revealed that booster shots of mRNA vaccines are needed to provide immunity against Omicron.